In plain words

In the two anxiety trials in the ledger, people taking ashwagandha ended with lower anxiety scores. A US health agency still calls the evidence on anxiety unclear.

The short answer

Both anxiety trials found lower scores with ashwagandha: 40 insomnia patients over 8 weeks (Langade and colleagues, 2020), and stressed healthy adults over 60 days, where it was associated with a lower Hamilton score than placebo (Lopresti and colleagues, 2019); the ledger has no dose for either and no n for the second. A 2014 review reported that two of three earlier placebo-controlled studies found a significant benefit. Three pooled analyses may include these trials, adding no separate evidence. NCCIH (2023) calls the evidence unclear. Certainty is low: only two trials, one with no n in the ledger, and a 2022 pooled analysis rated its evidence low.

The 60-second version

Every study in the video is listed below, with its quote.

Watch on YouTube

Where the evidence sits

Anxiety scores fell

■ Randomized trial, Langade et al., 2020 · 40 people · 8-weeks
■ Randomized trial, Lopresti et al., 2019 · ledger has no n
◪ Pooled analysis, Akhgarjand et al., 2022 · may overlap studies counted here
◪ Pooled analysis, BJPsych Open systematic review and meta-analysis, 2025 · may overlap studies counted here
◪ Pooled analysis, Cheah et al., 2021 · may overlap studies counted here
□ Review, Pratte et al., 2014 · summarises other studies

Unclear or no effect

□ Reported by: NCCIH (NIH), 2023; Steven Novella, 2023 · no new data

■ measured by the source's own study · ◪ pooled analysis, may overlap studies counted here · □ reported, reviewed or argued, no new data

Evidence weight5454 / 100?

Who says what

SourceFindingDesignPeopleDose and lengthFunding and independence
Langade et al., 2020HAM-A improvedRandomized trial40 insomnia patients8 weeks; dose not in ledgerNot in ledger
Lopresti et al., 2019HAM-A lower than placeboRandomized, placebo-controlledStressed healthy adults; n not in ledger60 days; dose not in ledgerNot in ledger
Akhgarjand et al., 2022Anxiety lowerMeta-analysis; may include the trials above1,002Not in ledgerNot in ledger
BJPsych Open review, 2025Anxiety lowerMeta-analysis; may include the trials aboveNot in ledgerNot in ledgerNot in ledger
Cheah et al., 2021HAM-A lowerMeta-analysis; may include the trials above189Not in ledgerNot in ledger
Pratte et al., 2014Benefit in most studiesReview describing earlier studiesNot in ledgerNot in ledgerNot in ledger
NCCIH, 2023Evidence unclearGovernment health summaryNoneNoneUS National Institutes of Health
Novella, 2023Positives may be falseBlog commentaryNoneNoneNo new data
Langade et al., 2020

HAM-A improved

Design
Randomized trial
People
40 insomnia patients
Dose and length
8 weeks; dose not in ledger
Funding
Not in ledger
Lopresti et al., 2019

HAM-A lower than placebo

Design
Randomized, placebo-controlled
People
Stressed healthy adults; n not in ledger
Dose and length
60 days; dose not in ledger
Funding
Not in ledger
Akhgarjand et al., 2022

Anxiety lower

Design
Meta-analysis; may include the trials above
People
1,002
Dose and length
Not in ledger
Funding
Not in ledger
BJPsych Open review, 2025

Anxiety lower

Design
Meta-analysis; may include the trials above
People
Not in ledger
Dose and length
Not in ledger
Funding
Not in ledger
Cheah et al., 2021

HAM-A lower

Design
Meta-analysis; may include the trials above
People
189
Dose and length
Not in ledger
Funding
Not in ledger
Pratte et al., 2014

Benefit in most studies

Design
Review describing earlier studies
People
Not in ledger
Dose and length
Not in ledger
Funding
Not in ledger
NCCIH, 2023

Evidence unclear

Design
Government health summary
People
None
Dose and length
None
Funding
US National Institutes of Health
Novella, 2023

Positives may be false

Design
Blog commentary
People
None
Dose and length
None
Funding
No new data

What did the two anxiety trials find?

Langade and colleagues (2020) reported improved Hamilton Anxiety Rating Scale (HAM-A) scores in 40 insomnia patients over 8 weeks; the ledger has no dose, and no placebo comparison, for this result. Lopresti and colleagues (2019) compared ashwagandha with placebo in stressed healthy adults for 60 days, and the ledger has no n or dose for that trial:

In comparison with the placebo, ashwagandha supplementation was associated with a statistically significant reduction in the HAM-A ( P = .040)

What did earlier studies report?

Pratte and colleagues (2014), writing before both trials above, reported that two of three placebo-controlled studies on the Hamilton scale found a significant benefit and the third came close; the ledger has no n, dose or duration for them. The reviewers added:

Current evidence should be received with caution because of an assortment of study methods and cases of potential bias.

What do the pooled analyses add?

Akhgarjand and colleagues (2022) pooled 12 randomized controlled trials with 1,002 participants, an estimate that may include the trials above, and found lower anxiety than with placebo (SMD -1.55), with high heterogeneity; the ledger has no dose or duration for it. They graded their own result:

Finally, we identified that the certainty of the evidence was low for both outcomes.

Cheah and colleagues (2021) found lower scores too. So did a 2025 BJPsych Open review; both pooled estimates may include the same trials. The ledger has no dose or duration for either.

Why do some sources call it unclear?

NCCIH, part of the US National Institutes of Health, summarized the research in 2023:

However, evidence is unclear about its effects on anxiety.

Steven Novella argued at Science-Based Medicine in 2023, from past anxiety drug research rather than new data, that positive results like these may be false positives until large rigorous trials are done.

Why the sources disagree

The people differ: insomnia patients, stressed healthy adults, and, in the 2025 review, people with mental disorders. The Langade result in the ledger is change over time, while Lopresti's is against placebo. The 2022 pooled estimate, which may include the trials above, had high heterogeneity, and Pratte rated every study it reviewed at unclear or high risk of bias. NCCIH and Novella weigh other people's studies; neither ran one. The ledger has no funding for any study here.

What would settle it

A pre-registered, independently funded trial in about 400 adults with diagnosed anxiety, randomized to a fixed daily dose of one standardized root extract or placebo for 12 weeks, reporting HAM-A against placebo at the end and 4 weeks after stopping. A matching result from a second research group would raise certainty from low to moderate.

How this page was made

The 8 sources are six studies and reviews from a PubMed literature search and two public summaries (NCCIH and Science-Based Medicine). Studies of animals, and of people with schizophrenia or on chemotherapy, were left out, as were claims on sleep, hormones and side effects. Every claim was copied word for word into the Longevity Circle ledger and checked against the original text, and a person approved each one. Certainty follows the GRADE levels used in medical reviews. Drafting was assisted by AI.

Changelog: 23 Sep 2026, first version, 8 sources.